Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting

JACC: Cardiovascular Interventions

Volumn 5, Issue 3, 2012, Pages 268-277

  Valgimigli, Marco ^a   Tebaldi, Matteo ^a   Campo, Gianluca ^a   Gambetti, Stefania ^b   Bristot, Laura ^a   Monti, Monia ^a   Parrinello, Giovanni ^c   Ferrari, Roberto ^a,d  

^a UNIVERSITY OF FERRARA   (Italy)

^b Medical Trial Analysis   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d IRCCS   (Italy)

Author keywords

aggregometry; bolus; clopidogrel; prasugrel; tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PRASUGREL; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; EX VIVO STUDY; FEMALE; HEART REINFARCTION; HUMAN; LIGHT SCATTERING; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STENTS; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 84858760413     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.01.006     Document Type: Article

References (23)

1. G. Campo, M. Valgimigli, D. Gemmati Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study J Am Coll Cardiol 48 2006 2178 2185 (Pubitemid 44873056)
2. A. Kastrati, J. Mehilli, F.J. Neumann Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial JAMA 295 2006 1531 1538
3. M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur Heart J 31 2009 35 49
4. M. Valgimigli, G. Campo, N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
5. A.W. Van't Hof, J. Ten Berg, T. Heestermans Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
6. Y.G. Li, L. Ni, J.T. Brandt Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects Platelets 20 2009 316 327
7. D.S. Small, N.A. Farid, C.D. Payne Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel Clin Pharmacokinet 49 2010 777 798
8. D.S. Small, Y.G. Li, C.S. Ernest 2nd Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent J Clin Pharmacol 51 2011 321 332
9. L. Bonello, M. Pansieri, J. Mancini High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
10. A.D. Michelson, A.L. Frelinger III, E. Braunwald Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
11. A.A. Heestermans, J.W. van Werkum, D. Taubert Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 2008 776 781
12. G. Campo, M. Valgimigli, D. Gemmati Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to- ticlopidine crossover study J Am Coll Cardiol 50 2007 1132 1137 (Pubitemid 47375009)
13. S. Holm A simple sequentially rejective multiple test procedure Scand J Statist 6 1979 65 70
14. D.S. Small, N.A. Farid, C.D. Payne Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel Clin Pharmacokinet 49 2010 777 798
15. D.S. Small, Y.G. Li, C.S. Ernest 2nd Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent J Clin Pharmacol 51 2011 321 332
16. E.J. Topol, D.J. Moliterno, H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894 (Pubitemid 32553357)
17. M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur Heart J 31 2010 35 49
18. S.D. Wiviott, E. Braunwald, C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
19. P. Lova, F. Campus, R. Lombardi Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin J Biol Chem 279 2004 25299 25306 (Pubitemid 38756783)
20. D.J. Angiolillo, D. Capodanno, S. Goto Platelet thrombin receptor antagonism and atherothrombosis Eur Heart J 31 2010 17 28
21. P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, U.S. Tantry Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study Circulation 111 2005 1153 1159 (Pubitemid 40365477)
22. G. Campo, L. Fileti, N. de Cesare et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial substudy J Am Coll Cardiol 56 2010 1447 1455
23. S.R. Steinhubl, J.D. Talley, G.A. Braden Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study Circulation 103 2001 2572 2578 (Pubitemid 32521967)